China's NMPA grants Priority Review to Zai's PARP inhibitor

Zai Lab Ltd. (NASDAQ:ZLAB) said it expects to launch Zejula niraparib in China next half now that China's National Medical Products Administration has granted Priority Review to an NDA for the PARP inhibitor as maintenance

Read the full 350 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE